Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796

Journal of Nuclear Medicine

Volumn 37, Issue 1, 1996, Pages 11-15

  Seibyl, John P ^a   Zea Ponce, Yolanda ^b   Brenner, Louise ^b   Baldwin, Ronald M ^b   Krystal, John H ^b   Offord, Steve J ^b   Mochoviak, Sandra ^b   Charney, Dennis S ^b   Hoffer, Paul B ^b   Innis, Robert B ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

antipsychotic agents; dopamine; dopamine receptor; SPECT

Indexed keywords

DOPAMINE RECEPTOR; IODINE 123; MAZAPERTINE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 2,3 DIHYDRO 5 IODOBENZOFURAN 7 CARBOXAMIDE; NEUROLEPTIC AGENT; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; AKATHISIA; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CORPUS STRIATUM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; CONTRAST MEDIA; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; MALE; PIPERAZINES; PYRROLIDINES; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 9244229013     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Farde L, Nordström A, Wiesel F, Pauli S, Hallidin C, Sedvall G Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
2. 123I]IBZM. J Nucl Med 1992,33:1964-1971
3. Kung H, Alavi A, Chang W, et al In vivo SPECT imaging of CNS D2 dopamine receptors: initial studies with iodine I-123-IBZM in humans. J Nucl Med 1990;31. 573-579.
4. 123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 1992;10:177-784
5. Barnes TR A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154 672-676.
6. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (suppl) 1970;212.11-19
7. Savic I, Roland P, Sedvall G, Persson A, Pauli S, Widen L In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988,2 863-866.
8. 11C]raclpride binding to D2 dopamine receptors studies with PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989;9:696-708.
9. 18F]cyclofoxy and positron emission tomography J Cereb Blood Flow Metab 1993;13:24-42
10. Farde L. Quantitative analysis of D2 dopasmine receptor binding in the living human brain with PET. Science 1986,231:258-261
11. Iyo M, Itoh T, Yamasaki T, et al Quantitative in vivo analysis of benzodiazepine binding sues in the human brain using positron emission tomography Neuropharmacology 1991,30:207-215.
12. 11C]Ro 15-1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow Metab 1989,8:304-313
13. Bylund D, Yamamura H Methods for receptor binding. In: Yamamura H, Enna S, Kuhar M, eds. Methods in neuroreceptor receptor analysis New York: Raven Press, 1990;1-35
14. 123I]iomazenil kinetic and equilibrium paradigms J Nucl Med 1994,35:228-238.
15. Wiesel FA, Farde L, Nordström AL, Sedvall G, Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog Neuropyschopharmacol Biol Psychiatry 1990,14:759-767.
16. Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235
17. Wong DF, Yung BCK, Giorgianni JA, et al D2 dopamine receptor occupancy as a function of rising dose of RWJ-37796 m normal living brain [Abstract] J Nucl Med 1993,34(suppl).109P